In a recent discussion on the long-term efficacy and safety of TT field treatment for lung cancer, Allen Wilbanks raised an important question. Ticiana Leal, MD, an esteemed expert from the Winship Cancer Institute of Emory University, provided valuable insights into this topic.
Dr. Leal began by highlighting the extensive experience with TT field treatment in patients with glioblastoma. She noted that real-world results for glioblastoma patients have consistently shown efficacy, safety, and improved quality of life, aligning with the landmark trials that led to the approval of TT fields in conjunction with temozolomide.
Transitioning to non-small cell lung cancer, Dr. Leal emphasized that the research is still evolving, with a randomized phase three study indicating overall survival benefits and maintaining safety and quality of life for patients. However, she acknowledged that the median follow-up in their study was approximately 10 months, indicating the need for more long-term data.
Dr. Leal expressed her commitment to ongoing research in this field, stating that they will continue to monitor long-term outcomes in non-small cell lung cancer through the lunar trial and real-world studies, should TT field treatment gain approval for this indication. Additionally, she highlighted the upcoming results from frontline studies involving immune checkpoint inhibitors and locally advanced patients, as well as the ongoing exploration of the safety of this combination strategy.
To gain a deeper understanding of TT field treatment's long-term efficacy and safety in lung cancer, viewers are invited to watch the full video discussion featuring Dr. Ticiana Leal's expert insights.